The AAFP concludes that evidence is insufficient to recommend for or against routine screening for elevated blood lead levels in asymptomatic children aged 1 to 5 years who are at increased risk.
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
K-O: Recommendations for Clinical Preventive Services
Lead Poisoning, Children
Lead Poisoning, Children
The AAFP recommends against routine screening for elevated blood levels in asymptomatic children aged 1 to 5 years who are at average risk.
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Lead Poisoning, Pregnant Women
The AAFP recommends against routine screening for elevated blood levels in asymptomatic pregnant women.
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf06/lead/leadrs.htm#Clinical
Lipid Disorders, Adults
The AAFP recommends screening men aged 35 and older for lipid disorders.
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders, Adults
The AAFP recommends screening women aged 45 and older for lipid disorders if they are at increased risk for coronary heart disease.
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders, Adults
The AAFP recommends screening men aged 20 to 35 for lipid disorders if they are at increased risk for coronary heart disease.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders, Adults
The AAFP recommends screening women aged 20 to 45 for lipid disorders if they are at increased risk for coronary heart disease.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders, Adults
The AAFP makes no recommendation for or against routine screening for lipid disorders in men aged 20 to 35, or in women aged 20 and older who are not at increased risk for coronary heart disease.
(Grade: C recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: C recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lipid Disorders, Infants, Children, Adolescents, and Young Adults
The AAFP concludes that the evidence is insufficient to recommend for or against routine screening for lipid disorders in infants, children, adolescents, or young adults (up to age 20).
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Considerations: www.ahrq.gov/clinic/uspstf08/lipid/lipidrs.htm#clinical
Lung Cancer
The AAFP recommends against the use of chest X-ray and/or sputum cytology in asymptomatic persons for lung cancer screening.
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf/uspslung.htm
Clinical Consideration: http://www.ahrq.gov/clinic/uspstf/uspslung.htm
Neural tube defects, Preventive, Folic Acid Supplementation, Women
The AAFP recommends that all women planning or capable of pregnancy take a daily supplement containing 0.43 to 0.8 mg (400 to 800 µg) of folic acid.
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Consideration: www.ahrq.gov/clinic/uspstf09/folicacid/folicacidrs.htm#clinical
(Grade: A recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/gradespost.htm#arec)
Clinical Consideration: www.ahrq.gov/clinic/uspstf09/folicacid/folicacidrs.htm#clinical
Obesity, Adults
The AAFP recommends that family physicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss for obese adults. Intensive counseling involves more than one session per month for at least 3 months.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsobes.htm
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsobes.htm
Obesity, Children and Adolescents
The AAFP recommends that clinicians screen children aged 6 years and older for obesity and offer them or refer them to comprehensive, intensive behavioral interventions to promote improvement in weight status
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration (The definations for specific interventions (targeted to diet and physical activity) and intensity (>25 hours with child and/or family over 6 months) are noted in the clinical considerations section: http://www.ahrq.gov/clinic/uspstf10/childobes/chobesrs.htm#clinical
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration (The definations for specific interventions (targeted to diet and physical activity) and intensity (>25 hours with child and/or family over 6 months) are noted in the clinical considerations section: http://www.ahrq.gov/clinic/uspstf10/childobes/chobesrs.htm#clinical
Oral Cancer, Adults
The AAFP concludes that the evidence is insufficient to recommend for or against routinely screening adults for oral cancer.
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsoral.htm
(Grade: I recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf/uspsoral.htm
Osteoporosis, Women
The AAFP recommends routinely screening women aged 65 and older for osteoporosis.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Osteoporosis, Women
The AAFP recommends routinely screening women aged 60 and older at increased risk for osteoporotic fractures.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Osteoporosis, Adolescents, Young Women, Women
The AAFP recommends counseling females age 11 and older to maintain adequate calcium intake prevent osteoporosis.
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Clinical Considerations:
www.ahrq.gov/clinic/3rduspstf/osteoporosis/osteorr.htm#consideration
Ovarian Cancer, Women
The AAFP recommends against routine screening for ovarian cancer.
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Considerations: www.ahrq.gov/clinic/uspstf/uspsovar.htm
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Considerations: www.ahrq.gov/clinic/uspstf/uspsovar.htm
Ovarian Cancer/BRCA Mutation Testing
The AAFP recommends that women whose family history is associated with an increased risk for deleterious mutations in BRCA1 or BRCA2 genes be referred for genetic counseling and evaluation for BRCA testing.
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
(Grade: B recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
Ovarian Cancer/BRCA Mutation Testing
The AAFP recommends against routine referral for genetic counseling or routine breast cancer susceptibility gene (BRCA) testing for women whose family history is not associated with increased risk for deleterious mutations in breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2).
(Grade: D recommendation)
(Grade Definition: http://www.ahrq.gov/clinic/uspstf/grades.htm#pre)
Clinical Consideration: www.ahrq.gov/clinic/uspstf05/brcagen/brcagenrs.htm#clinical
